"Tethered-Addressed" Drugs for the Treatment of Cancer

Focus: 

To optimize and test targeted small-molecule therapeutics for cancer

Anticipated Impact: 

Safer and more effective cancer treatments

Abstract: 

RJS Biologics is developing a novel approach to cancer treatment that uses affinity tags to drive therapeutic compounds into tumor cells. This targeted approach—which could be used for both existing and novel chemotherapeutic agents for a variety of cancer types—is anticipated to improve both the efficacy and safety of therapy by maximizing tumor uptake while minimizing uptake by normal cells. This grant will demonstrate the general utility of RJSBio’s technology by optimizing agents for multiple cancers and assessing their in vivo efficacy. The company anticipates that LSDF support will help attract grant and private financing to continue preclinical and clinical development.

Collaborating organization: University of Washington

Cancer Diagnostics, Therapeutics

Grant Update

Principal Investigator:
Stephen McCraith
Grantee Organization:
RJS Biologics, LLC
Grant Title:
Tethered-Addressed Drugs for the Treatment of Cancer.
Grant Cohort and Year:
2013 Proof of Concept (03)
Grant Period:
06/01/2013 - 05/31/2015 (Completed)
Grant Amount:
$250,000
A cancer drug’s journey to its intended target is a key component to its ultimate success. RJS Biologics has developed novel cancer drugs with the help of Washington State’s Life Science Discovery Fund. These new drugs are transported by cellular pathways which are over-represented in cancer cells and may be better at selecting cancerous cells than currently used drugs. Such specificity is a critical component in the fight against cancer as it protects patients from the harmful side effects of their drugs. RJS Biologics has improved the capabilities of numerous cancer drugs to reach their intended cell target. Specificity for cancer cells has been designed and manufactured directly into a series of drug candidates. These new drugs have demonstrated an increase in cancer specific potency of approximately 7-8 fold in cell based assays of cancer versus normal cells.

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact
Seattle

Legislative Districts:
11, 34, 36, 37, 43, 46

Health Impacts

Cancer Diagnostics, Therapeutics